Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2026)

Vivos Therapeutics (VVOS) has 6 years of Return on Capital Employed data on file, last reported at 315.56% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 18384.0% year-over-year to 315.56% in Q1 2026; TTM through Mar 2026 was 315.56%, a 18384.0% decrease from a year earlier, with the FY2025 full-year figure at 928.76%, down 78963.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 315.56%, down from 271.77% in the prior quarter.
• Over the last five years, Return on Capital Employed for VVOS reached as high as 88.7% in Q3 2025 and fell as low as 534.7% in Q4 2023.
• Historically, Return on Capital Employed has averaged 238.5% across 5 years, with a median of 187.94% in 2024.
• Across the five-year window, Return on Capital Employed slumped 26356 bps in 2023 and soared 42663 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 271.15% in 2022, then tumbled by 97 bps to 534.7% in 2023, then surged by 80 bps to 108.07% in 2024, then plunged by 151 bps to 271.77% in 2025, then fell by 16 bps to 315.56% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 315.56% in Q1 2026, 271.77% in Q4 2025, and 88.7% in Q3 2025.